Objective:To explore the effect of the adjuvant milrinone therapy on cardiac function, myocardial remodeling and RAAS system activity in patients with chronic heart failure. Methods: A total of 110 patients with chron...Objective:To explore the effect of the adjuvant milrinone therapy on cardiac function, myocardial remodeling and RAAS system activity in patients with chronic heart failure. Methods: A total of 110 patients with chronic heart failure who were treated in the hospital between January 2015 and January 2017 were divided into control group (n=55) and observation group (n=55) by random number table method. Control group received conventional therapy for chronic heart failure, and the observation group received milrinone on the basis of conventional therapy. The differences in ultrasound cardiac function and myocardial remodeling index levels as well as serum RAAS index contents were compared between the two groups before and after treatment.Results: Before treatment, the differences in ultrasound cardiac function and myocardial remodeling index levels as well as serum RAAS index contents were not statistically significant between the two groups. After treatment, CO and SV levels of both groups of patients were significantly higher than those before treatment while LADd, LVEDd, LVPWT, IVST and LVMI levels as well as serum PRA, AngⅡ and ALD contents were significantly lower than those before treatment, and CO and SV levels of observation group were significantly higher than those of control group while LADd, LVEDd, LVPWT, IVST and LVMI levels as well as serum PRA, AngⅡ and ALD contents were significantly lower than those of control group.Conclusion: Adjuvant milrinone therapy can effectively enhance the cardiac function, inhibit the myocardial remodeling and decrease the RAAS system activity in patients with chronic heart failure.展开更多
To systematically evaluate the efficacy of urinary granules combined with RAAS system blockers in the treatment of diabetic nephropathy(DN).A meta-analysis of the data required in the literature in accordance with thi...To systematically evaluate the efficacy of urinary granules combined with RAAS system blockers in the treatment of diabetic nephropathy(DN).A meta-analysis of the data required in the literature in accordance with this study was performed using Rev Man 5.3 software.Fifteen randomized controlled trials were analyzed in the present study to evaluate the clinical effect of Niaoduqing-angiotensin converting enzyme inhibitors/angiotensin receptor blocker(ACEI/ARB)in DN patients.A total of 1063 patients were involved,including 538 patients receiving the combination treatment and 525 patients in the control group.The results showed that the clinical efficacy of Niaoduqing granule combined with ACEI/ARB was significantly better than of the control group(odds ratio=2.92,95%confidence interval[CI]1.76–4.86).The treatment combined with Niaoduqing granule decreased the 24-h urinary protein quantitation(mean difference[MD]0.71,95%CI 0.28–1.14)and urine albumin excretion rate(UAER)(MD 41.13,95%CI 26.66–55.59)levels.However,the combination group had no treatment advantage on reducing serumurea nitrogen(MD 0.86,95%CI 0.05–1.68,P=0.02)and fasting blood glucose(MD-0.03,95%CI-0.15–0.09,P=0.61).And there was no significance in adverse events between two groups(risk ratio=2.34,95%CI 0.69–7.95,P=0.17).Niaoduqing granule-ACEI/ARB combination group maybe as safe as ACEI/ARB alone,and the combination played an advantage in improvement in total effective rate,reduction of 24-h urinary protein quantitation and UAER.展开更多
目的分析老年高血压患者群体中肾素-血管紧张素-醛固酮系统(RAAS)标志物与24 h动态血压参数之间的关联性。方法选取2023年1月至2024年6月永安市立医院收治的老年高血压患者患者106例,根据高血压病情严重程度划分为低度组(28例)、中度组...目的分析老年高血压患者群体中肾素-血管紧张素-醛固酮系统(RAAS)标志物与24 h动态血压参数之间的关联性。方法选取2023年1月至2024年6月永安市立医院收治的老年高血压患者患者106例,根据高血压病情严重程度划分为低度组(28例)、中度组(45例)和重度组(33例)。对比分析三组血管紧张素转换酶(ACE)、肾素(RA)、血管紧张素II(AngII)及醛固酮(ALD)等血清RAAS标志物,以及24 h全时段、日间活动期及夜间静息期等不同时相的收缩压与舒张压数据,包括整体均值(24 hSBP/24 hDBP)、日间均值(dSBP/dDBP)及夜间均值(nSBP/nDBP)等动态血压参数。采用Pearson相关分析法探讨血清RAAS指标与动态血压参数间的相关性。结果重度组ACE、RA、AngII和ALD显著高于轻度和中度组,中度组显著高于轻度组[(101.14±11.42 vs 83.36±6.11 vs 78.34±9.14)U/L、(3.25±0.32 vs 2.78±0.27 vs 2.12±0.26μg/L、55.56±6.49 vs 42.23±6.98 vs 35.36±5.11 ng/L、201.58±20.12 vs 172.81±16.12vs 144.78±13.87)ng/L],差异有统计学意义(P<0.05);重度组24 hSBP、24 hDBP、dSBP、dDBP、nSBP和nDBP均显著高于轻度和中度组,中度组显著高于轻度组[(181.57±13.41 vs 149.27±11.52 vs 135.24±8.55)、(103.47±12.18 vs96.74±7.41 vs 78.73±5.47)、(173.56±9.39 vs 148.24±10.34 vs 139.42±8.31)、(105.45±11.21 vs 96.35±6.34 vs 82.76±5.39)、(164.76±13.14 vs 144.36±6.11 vs 124.34±8.14)、(98.74±8.69 vs 90.12±7.76 vs 73.78±8.87)]mmHg,差异有统计学意义(P<0.05);老年高血压患者ACE、RA、AngII和ALD等血清RAAS标志物浓度与24 hSBP、24 hDBP、dSBP、dDBP、nSBP和nDBP等动态血压参数正相关(P<0.05)。结论老年高血压患者的RAAS标志物水平与病情程度及动态血压参数密切相关,监测血清RAAS标志物水平可能有助于评估老年高血压患者的血压控制情况及病情严重程度,为个体化治疗提供重要参考。展开更多
文摘Objective:To explore the effect of the adjuvant milrinone therapy on cardiac function, myocardial remodeling and RAAS system activity in patients with chronic heart failure. Methods: A total of 110 patients with chronic heart failure who were treated in the hospital between January 2015 and January 2017 were divided into control group (n=55) and observation group (n=55) by random number table method. Control group received conventional therapy for chronic heart failure, and the observation group received milrinone on the basis of conventional therapy. The differences in ultrasound cardiac function and myocardial remodeling index levels as well as serum RAAS index contents were compared between the two groups before and after treatment.Results: Before treatment, the differences in ultrasound cardiac function and myocardial remodeling index levels as well as serum RAAS index contents were not statistically significant between the two groups. After treatment, CO and SV levels of both groups of patients were significantly higher than those before treatment while LADd, LVEDd, LVPWT, IVST and LVMI levels as well as serum PRA, AngⅡ and ALD contents were significantly lower than those before treatment, and CO and SV levels of observation group were significantly higher than those of control group while LADd, LVEDd, LVPWT, IVST and LVMI levels as well as serum PRA, AngⅡ and ALD contents were significantly lower than those of control group.Conclusion: Adjuvant milrinone therapy can effectively enhance the cardiac function, inhibit the myocardial remodeling and decrease the RAAS system activity in patients with chronic heart failure.
基金supported by the National Natural Science Foundation Project of China (youth science fund project. 81603570)
文摘To systematically evaluate the efficacy of urinary granules combined with RAAS system blockers in the treatment of diabetic nephropathy(DN).A meta-analysis of the data required in the literature in accordance with this study was performed using Rev Man 5.3 software.Fifteen randomized controlled trials were analyzed in the present study to evaluate the clinical effect of Niaoduqing-angiotensin converting enzyme inhibitors/angiotensin receptor blocker(ACEI/ARB)in DN patients.A total of 1063 patients were involved,including 538 patients receiving the combination treatment and 525 patients in the control group.The results showed that the clinical efficacy of Niaoduqing granule combined with ACEI/ARB was significantly better than of the control group(odds ratio=2.92,95%confidence interval[CI]1.76–4.86).The treatment combined with Niaoduqing granule decreased the 24-h urinary protein quantitation(mean difference[MD]0.71,95%CI 0.28–1.14)and urine albumin excretion rate(UAER)(MD 41.13,95%CI 26.66–55.59)levels.However,the combination group had no treatment advantage on reducing serumurea nitrogen(MD 0.86,95%CI 0.05–1.68,P=0.02)and fasting blood glucose(MD-0.03,95%CI-0.15–0.09,P=0.61).And there was no significance in adverse events between two groups(risk ratio=2.34,95%CI 0.69–7.95,P=0.17).Niaoduqing granule-ACEI/ARB combination group maybe as safe as ACEI/ARB alone,and the combination played an advantage in improvement in total effective rate,reduction of 24-h urinary protein quantitation and UAER.
文摘目的分析老年高血压患者群体中肾素-血管紧张素-醛固酮系统(RAAS)标志物与24 h动态血压参数之间的关联性。方法选取2023年1月至2024年6月永安市立医院收治的老年高血压患者患者106例,根据高血压病情严重程度划分为低度组(28例)、中度组(45例)和重度组(33例)。对比分析三组血管紧张素转换酶(ACE)、肾素(RA)、血管紧张素II(AngII)及醛固酮(ALD)等血清RAAS标志物,以及24 h全时段、日间活动期及夜间静息期等不同时相的收缩压与舒张压数据,包括整体均值(24 hSBP/24 hDBP)、日间均值(dSBP/dDBP)及夜间均值(nSBP/nDBP)等动态血压参数。采用Pearson相关分析法探讨血清RAAS指标与动态血压参数间的相关性。结果重度组ACE、RA、AngII和ALD显著高于轻度和中度组,中度组显著高于轻度组[(101.14±11.42 vs 83.36±6.11 vs 78.34±9.14)U/L、(3.25±0.32 vs 2.78±0.27 vs 2.12±0.26μg/L、55.56±6.49 vs 42.23±6.98 vs 35.36±5.11 ng/L、201.58±20.12 vs 172.81±16.12vs 144.78±13.87)ng/L],差异有统计学意义(P<0.05);重度组24 hSBP、24 hDBP、dSBP、dDBP、nSBP和nDBP均显著高于轻度和中度组,中度组显著高于轻度组[(181.57±13.41 vs 149.27±11.52 vs 135.24±8.55)、(103.47±12.18 vs96.74±7.41 vs 78.73±5.47)、(173.56±9.39 vs 148.24±10.34 vs 139.42±8.31)、(105.45±11.21 vs 96.35±6.34 vs 82.76±5.39)、(164.76±13.14 vs 144.36±6.11 vs 124.34±8.14)、(98.74±8.69 vs 90.12±7.76 vs 73.78±8.87)]mmHg,差异有统计学意义(P<0.05);老年高血压患者ACE、RA、AngII和ALD等血清RAAS标志物浓度与24 hSBP、24 hDBP、dSBP、dDBP、nSBP和nDBP等动态血压参数正相关(P<0.05)。结论老年高血压患者的RAAS标志物水平与病情程度及动态血压参数密切相关,监测血清RAAS标志物水平可能有助于评估老年高血压患者的血压控制情况及病情严重程度,为个体化治疗提供重要参考。
